Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Lancet Neurol. 2015 Jun 23;14(8):795–803. doi: 10.1016/S1474-4422(15)00144-1

Figure 2. Change in total Unified Parkinson's Disease Rating Scale (UPDRS) over time by treatment group.

Figure 2

Means (95% CI) are adjusted for site, time on rasagiline or selegiline at baseline, and baseline UPDRS (from repeated measures mixed model). Assessments on participants taking additional symptomatic therapy were excluded.